CDC42 and neoplasm: Characterization of MBQ-167 is one of only a few studies to take a Cdc42 inhibitor into a preclinical mouse model, where it inhibited HER-2 type tumour growth and metastasis in immunocompromised mice by 90% [36] The pharmacokinetic profiles of the small molecule were also evaluated, with relative bioavailability reported to be 35% with an oral half-life of 2.6 hours [37].